⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7662948 | 0.72 | — | — | |
| SCHEMBL6246068 | 0.71 | — | — | |
| SCHEMBL6220567 | 0.65 | — | — | |
| SCHEMBL349705 | 0.64 | — | — | |
| SCHEMBL10378156 | 0.63 | CYP2D6 (0.30) | — | |
| SCHEMBL9575649 | 0.63 | CYP2D6 (0.30) | — | |
| SCHEMBL348991 | 0.62 | — | — | |
| SCHEMBL679048 | 0.62 | — | — | |
| SCHEMBL397950 | 0.61 | — | — | |
| SCHEMBL8424512 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | claimed |
| EP-2291359-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| WO-2009142569-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| EP-1797051-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | claimed |
| WO-2006037481-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016173948-A1 | INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | WO | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1797051-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006037481-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |